932226-24-9

Usage

Uses

Used in Organic Synthesis:
2,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde is utilized as a starting material in organic synthesis for the preparation of heterocyclic compounds. Its unique structure and functional groups make it a valuable building block for creating a variety of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde is employed as a starting material for the development of pharmaceuticals. Its distinctive structural features and functional groups contribute to the design and synthesis of potential new drugs with therapeutic applications.
Used in Fluorine Chemistry:
2,5-dimethyl-1-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carbaldehyde is used as a valuable tool in fluorine chemistry. Its trifluoromethyl group makes it instrumental in the study of fluorinated organic molecules, which can possess unique properties and applications in various fields.

Upstream product

• 88-17-5 2-(trifluoromethyl)benzenamine 
• 571-66-4 2,5-dimethyl-1-(2-(trifluoromethyl)phenyl)-1H-pyrrole 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1445610-37-6 C₂₁H₁₉F₃N₂O₃ 
• 1428184-13-7 C₂₂H₂₃F₃N₂O₃ 
• 1428184-12-6 C₂₃H₂₃F₃N₂O₃ 
• 1428184-11-5 C₂₄H₂₇F₃N₄O₂ 
• 1428184-10-4 C₂₆H₃₁F₃N₄O₂ 
• 1428184-09-1 C₂₂H₂₂F₃N₃O₃ 
• 1428184-08-0 C₂₄H₂₆F₃N₃O₃ 
• 1428184-07-9 C₂₄H₂₄F₃N₃O₃ 
• 1428184-06-8 C₂₅H₂₆F₃N₃O₂ 
• 1428184-05-7 C₂₁H₂₀F₃N₃O₂ 
• 1428184-04-6 C₂₀H₁₈F₃N₃O₂ 
• 1428184-02-4 C₂₀H₁₇F₃N₂O₃ 

Relevant academic research and scientific papers

Improving the Potency of N-Aryl-2,5-dimethylpyrroles against Multidrug-Resistant and Intracellular Mycobacteria

A series of N-phenyl-2,5-dimethylpyrrole derivatives, designed as hybrids of the antitubercular agents BM212 and SQ109, have been synthesized and evaluated against susceptible and drug-resistant mycobacteria strains. Compound 5d, bearing a cyclohexylmethylene side chain, showed high potency against M. tuberculosis including MDR-TB strains at submicromolar concentrations. The new compound shows bacteriostatic activity and low toxicity and proved to be effective against intracellular mycobacteria too, showing an activity profile similar to isoniazid.

Synthesis, structure and in vitro anti-trypanosomal activity of non-toxic arylpyrrole-based chalcone derivatives

With an intention of identifying chalcone derivatives exhibiting anti-protozoal activity, a cohort of relatively unexplored arylpyrrole-based chalcone derivatives were synthesized in moderate to good yields. The resultant compounds were evaluated in vitro for their potential activity against a cultured Trypanosoma brucei brucei 427 strain. Several compounds displayed mostly modest in vitro anti-trypanosomal activity with compounds 10e and 10h emerging as active candidates with IC50 values of 4.09 and 5.11 μM, respectively. More importantly, a concomitant assessment of their activity against a human cervix adenocarcinoma (HeLa) cell line revealed that these compounds are non-toxic.

Discovery and optimisation studies of antimalarial phenotypic hits

There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09e29 mM, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds.

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.